Repositioning Candidate Details
| Candidate ID: | R0444 |
| Source ID: | DB06288 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Amisulpride |
| Synonyms: | |
| Molecular Formula: | C17H27N3O4S |
| SMILES: | CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC |
| Structure: |
|
| DrugBank Description: | Amisulpride (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist. |
| CAS Number: | 71675-85-9 |
| Molecular Weight: | 369.479 |
| DrugBank Indication: | Investigated for use/treatment in schizophrenia and schizoaffective disorders, mania in bipolar disorder, and depression. |
| DrugBank Pharmacology: | |
| DrugBank MoA: | Amisulpride binds selectively to dopamine D(2) and D(3) receptors in the limbic system. Low doses of amisulpride preferentially block presynaptic D(2)/D(3)-dopamine autoreceptors, thereby enhancing dopaminergic transmission, whereas higher doses block postsynaptic receptors, thus inhibiting dopaminergic hyperactivity. It may also have 5-ht7 antagonistic effect, useful in depression treatment. |
| Targets: | 5-hydroxytryptamine receptor 7; 5-hydroxytryptamine receptor 2A; Dopamine D2 receptor; Dopamine D3 receptor; Mu-type opioid receptor; Delta-type opioid receptor; Kappa-type opioid receptor |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|